GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
GLOW is a research blend of three peptides, BPC-157, TB-500 and GHK-Cu, supplied together as one lyophilized powder. Each component has its own preclinical literature, mostly in tissue-repair and skin-remodeling models; the three-peptide combination itself has not been studied as a blend. GHK-Cu is a copper-binding tripeptide studied in cell-culture and animal models of collagen synthesis, while BPC-157 and thymosin beta-4 (the parent peptide of TB-500) have been examined in rodent tissue-repair models.
Available Options
Research Context
Composition. Each vial is labelled to contain 10 mg BPC-157, 10 mg TB-500 and 50 mg GHK-Cu (70 mg in total), supplied as a single lyophilized powder. The batch Certificate of Analysis below reports identity for all three components by LC-MS and purity by HPLC. For what those results mean, see How to Read a Peptide COA and How to Read an HPLC Chromatogram.
GLOW combines three peptides that each appear in the preclinical tissue-repair literature: BPC-157, a stable pentadecapeptide derived from a protein found in human gastric juice; TB-500, a synthetic fragment corresponding to the actin-binding region of thymosin beta-4, a 43-amino-acid peptide present in most mammalian cells; and GHK-Cu, a naturally occurring copper-binding tripeptide first isolated from human plasma. Each component has its own distinct research history, and the blend format reflects a research interest in studying these compounds alongside one another rather than a single characterized molecular entity.
The evidence base for the individual components is almost entirely preclinical. BPC-157 has been examined extensively in rodent models of tendon, ligament, muscle, and gastrointestinal injury, with proposed mechanisms involving growth factor expression, angiogenesis, and nitric oxide system modulation; no completed human clinical trials of BPC-157 have been published. Thymosin beta-4, the parent peptide of TB-500, has been studied in vitro for its role in actin sequestration and cell migration, and in animal wound-healing models; the parent peptide has also seen limited early-phase human investigation in wound and ophthalmic settings, distinct from TB-500 itself. GHK-Cu has been characterized largely in vitro, where fibroblast and gene-expression studies report effects on collagen synthesis and matrix remodeling pathways, alongside animal skin models and small human topical studies of cosmetic formulations.
Notably, no published studies have examined this specific three-peptide combination as a blended preparation. Whether the components interact additively, synergistically, or competitively in shared model systems remains an open question, as do the pharmacokinetics and stability of the combined formulation. Researchers working with this blend are generally drawing on the single-compound literature summarized in our BPC-157 and TB-500 research overview and the GHK-Cu literature, and translating findings across models requires caution given differences in species, delivery route, and study design.
Specifications
| Labelled composition (per vial) | BPC-157 10 mg · TB-500 10 mg · GHK-Cu 50 mg (70 mg total) |
| Form | Lyophilized powder |
| Purity | >=99% (HPLC) |
| Identity testing | LC-MS, all three components (batch COA) |
| Storage | Store lyophilized at -20C; refrigerate (2-8C) after reconstitution |
Storage & Handling
Keep the sealed vial of lyophilized powder at -20C, dry and protected from light. Let a cold vial reach room temperature before opening, so moisture does not condense on the powder, and open it as rarely as possible. Temperature, moisture and light are the main drivers of degradation in dry peptides; see Lyophilized Peptide Stability.
After reconstitution, refrigerate at 2-8C and use the solution promptly.
For handling guidance, see our peptide reconstitution and storage guide, and use the reconstitution calculator to plan solution volumes for laboratory work.
Certificate of Analysis
🛡 COA — BPC-157 10mg / TB-500 10mg / GHK-Cu 50mgHow to read these reports: reading a COA · reading the HPLC chromatogram
Further Reading
Related Compounds
References
- Matek D et al. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review. Pharmaceuticals (Basel). 2026. PMID 41754849
- Faa G et al. Thymosin β4 and β10 Expression in Human Organs during Development: A Review. Cells. 2024. PMID 38994967
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMID 26236730